Myeloid precursors are the intermediate cells in your bone marrow that sit between multipotent stem cells and the finished blood cells your body relies on every day. They give rise to neutrophils, monocytes, red blood cells, platelets, and other cell types that fight infection, carry oxygen, and stop bleeding. Understanding them matters because disruptions at this stage of blood-cell production underlie some of the most common blood cancers, explain why infections cause specific changes on a blood test, and increasingly shape how researchers think about immunity and aging.
From Stem Cell to Myeloid Progenitor
All blood cells trace back to a single cell type in the bone marrow called the hematopoietic stem cell (HSC). This multipotent cell can form every type of blood and immune cell in the body. One of the earliest branching points in that process produces what is known as the common myeloid progenitor, the ancestor of the entire myeloid arm of blood-cell production.1PubMed Central. Myeloid Cell Origins, Differentiation, and Clinical Implications The other major branch gives rise to lymphoid cells, which include the T cells and B cells responsible for adaptive immunity. Myeloid precursors, then, are all the cells along the myeloid branch that have committed to becoming a myeloid cell type but have not yet finished maturing.
One striking finding is that stem cells can commit to the myeloid lineage remarkably quickly. In mouse studies, HSCs were shown to differentiate into restricted myeloid progenitors without even dividing first, before they entered the DNA-replication phase of the cell cycle.2Nature Communications. Hematopoietic stem cells can differentiate into restricted myeloid progenitors before cell division in mice That speed hints at how urgently the body can redirect its blood-cell factory when demand spikes, a theme that recurs throughout myeloid biology.
What Myeloid Precursors Become
The common myeloid progenitor branches further into increasingly specialized precursors. The two main downstream paths are the granulocyte-monocyte progenitor, which produces neutrophils, monocytes, and related white blood cells, and the megakaryocyte-erythroid progenitor (MEP), which produces red blood cells and platelets.
On the granulocyte side, the maturation sequence for neutrophils has been mapped in detail: myeloblasts give way to promyelocytes, then myelocytes, metamyelocytes, band cells, and finally the segmented mature neutrophils that circulate in your blood.3PubMed. Current knowledge on the early stages of human neutropoiesis Each stage is a bit more specialized and a bit closer to the finished product. The earliest stages are still poorly characterized, which is part of why researchers continue to refine the picture.
On the megakaryocyte-erythroid side, what was once assumed to be a single progenitor population turns out to be more complex. Single-cell profiling has revealed at least three distinct subpopulations within what had been called the MEP compartment: one enriched for early progenitors that still retain some myeloid potential, one strongly biased toward red blood cell production, and a rare population primarily geared toward making megakaryocytes, the giant cells that shed platelets.4PubMed Central. Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways The old textbook picture of a clean binary split between “red cell path” and “platelet path” is a simplification. The reality is more like a gradient, with cells at different points of commitment mixed together.
Emergency Production During Infection
Under normal conditions, blood-cell production hums along at a steady pace. During a serious infection, though, the body shifts into what researchers call emergency granulopoiesis, a rapid acceleration of neutrophil production to replace the huge numbers being consumed at the site of infection.5PubMed Central. Regulation of emergency granulopoiesis during infection This is where myeloid precursors become acutely visible to clinicians.
During emergency granulopoiesis, the bone marrow pushes immature neutrophils, including myelocytes, metamyelocytes, and band cells, out into the bloodstream before they are fully mature. This phenomenon is known as a “left shift,” a term that dates back to when lab instruments plotted cell maturity on a horizontal axis.6Frontiers in Immunology. Neutrophil Homeostasis and Emergency Granulopoiesis: The Example of Systemic Juvenile Idiopathic Arthritis A left shift on a blood count is one of the classic signs that the body is fighting something serious. It tells a doctor that the demand for neutrophils has outstripped the supply of mature ones, so the marrow is releasing cells early.
What Immature Granulocytes Tell Doctors
Modern blood analyzers can automatically count immature granulocytes, the cells released during a left shift. The presence of these cells in peripheral blood reflects active bone marrow response to infection.7PubMed Central. Automated Measurement of Immature Granulocytes: Performance Characteristics and Utility in Routine Clinical Practice This has clinical value beyond what a simple white blood cell count can offer.
In intensive care units, distinguishing infection from other causes of inflammation is a persistent challenge. A prospective study found that the immature granulocyte count could discriminate between infected and non-infected patients with about 89% sensitivity and 76% specificity within the first 48 hours, outperforming several other common lab markers for detecting infection early.8PubMed Central. Revisiting the white blood cell count: immature granulocytes count as a diagnostic marker to discriminate between SIRS and sepsis–a prospective, observational study Another ICU study found that the immature granulocyte percentage performed comparably to C-reactive protein in predicting microbial infection, and that a low immature granulocyte percentage was useful for ruling infection out.9PubMed. Immature granulocytes predict microbial infection and its adverse sequelae in the intensive care unit
These findings have made the immature granulocyte count a routine part of many complete blood count panels. It is not a perfect test for infection on its own, but as a quick, automated measurement that comes back with every blood draw, it gives clinicians an early signal that can prompt further investigation.
When Myeloid Precursors Go Wrong
Because myeloid precursors sit at a bottleneck in blood production, problems at this stage tend to have outsized consequences. The three major categories of myeloid disease each illustrate a different way the system can fail.
In acute myeloid leukemia (AML), immature myeloid precursors acquire mutations that block their ability to mature and cause them to multiply uncontrollably. The bone marrow fills with these stuck, immature cells, crowding out normal blood production.10PubMed Central. Differentiation therapy of acute myeloid leukemia This is the most common acute leukemia in adults. One therapeutic approach, called differentiation therapy, tries to force those arrested precursors to resume maturing rather than simply killing them with chemotherapy.
Myelodysplastic syndromes (MDS) present a different puzzle. In MDS, the bone marrow is often packed with cells, yet the patient’s blood counts are low. The explanation lies in excessive programmed cell death among the myeloid precursors: marrow cells are being produced but are dying prematurely before they can reach the bloodstream.11Clinical Leukemia. Increased Apoptosis as a Mechanism of Ineffective Erythropoiesis in Myelodysplastic Syndromes Studies of bone marrow biopsies from MDS patients consistently show significantly more precursor cell death than normal marrows.12PubMed. Apoptosis is a Common Histopathological Finding in Myelodysplasia: the Correlate of Ineffective Haematopoiesis
Myeloproliferative neoplasms (MPNs) are essentially the opposite problem: too many mature cells in the blood rather than too few. These disorders are driven by mutations, most commonly in the JAK2 gene, that cause signaling pathways in myeloid precursors to stay permanently switched on.13PubMed Central. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms The result is an overproduction of red blood cells, platelets, or white blood cells depending on which downstream lineage the mutation affects. MPNs also carry an increased risk of blood clots and, over time, can progress to AML.14Leukemia. Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm
Myeloid Precursors That Help Tumors Hide
Not all myeloid precursor problems involve blood cancers directly. In many solid tumors, the cancer itself hijacks normal myeloid development to build a protective shield. Under normal conditions, immature myeloid cells in the bone marrow mature into granulocytes, macrophages, and dendritic cells that patrol for threats. In cancer patients, chronic inflammatory signals from the tumor stall that maturation, causing immature myeloid cells to accumulate instead.15PubMed Central. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
These stuck cells, called myeloid-derived suppressor cells (MDSCs), are recruited to the tumor microenvironment where they actively suppress the immune response against the cancer. They do this through a variety of mechanisms: depleting nutrients that T cells need, producing reactive molecules that damage immune cells, and stimulating other immunosuppressive cell types.16PubMed. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment MDSCs are now recognized as one of the major barriers to effective cancer immunotherapy. A treatment that activates the immune system against a tumor may still fail if that tumor has recruited enough MDSCs to shut the immune response down locally. Targeting MDSCs, either by blocking their recruitment or forcing them to resume normal maturation, is an active area of drug development.
The Aging Myeloid Bias
As people age, their blood-forming stem cells shift toward producing more myeloid cells and fewer lymphoid cells. This “myeloid bias” is one of the most consistent findings in aging research. Aged human HSCs are more numerous but less capable of balanced output, generating proportionally more myeloid precursors at the expense of lymphocyte-producing ones.17PubMed Central. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age Gene expression studies show that aged HSCs upregulate genes tied to cell cycling, myeloid lineage commitment, and, tellingly, myeloid malignancies.
Recent work has identified specific molecular drivers of this shift. One study found that a protein called clusterin accumulates in aged HSCs and drives myeloid-biased differentiation by altering mitochondrial function.18Nature Aging. Clusterin drives myeloid bias in aged hematopoietic stem cells by regulating mitochondrial function The practical consequences of this age-related myeloid bias are far-reaching: it helps explain why older adults have weaker vaccine responses and are more susceptible to infections, since the lymphoid side of the immune system is getting shortchanged. It also creates a larger pool of myeloid precursors in which cancer-causing mutations can arise.
There is a related phenomenon called clonal hematopoiesis, where a single stem cell or myeloid-restricted progenitor acquires a mutation that gives it a growth advantage, and its descendants gradually come to dominate blood production. Clonal hematopoiesis is strongly linked to age and is increasingly viewed as a pre-leukemic state.19Cell Stem Cell. Large-Scale Clonal Analysis Resolves Aging of the Mouse Hematopoietic Stem Cell Compartment Researchers now consider both HSCs and self-renewing myeloid-restricted progenitors as potential origins of these dominant clones.
Trained Immunity and the Memory of Myeloid Cells
For decades, immunological memory was thought to belong exclusively to the adaptive immune system. Myeloid cells were considered reactive but amnesiac: they would respond to a threat and then return to baseline with no lasting change. That view has been upended by the discovery of trained immunity, a process by which myeloid cells and their bone marrow progenitors undergo long-term epigenetic and metabolic reprogramming after an initial stimulus, leaving them more responsive to future challenges.20Frontiers in Immunology. Induction of trained immunity in myeloid cells and their progenitors from thyroid cancer patients
This concept is being explored as a potential treatment strategy in cancer. If myeloid progenitors can be “trained” to mount a stronger innate immune response, they might help overcome the immunosuppressive tumor microenvironment that MDSCs work to maintain. The research is still early, but it reframes myeloid precursors from passive factory output into cells with their own form of adaptable, lasting responsiveness.
How Infections Reshape the Bone Marrow
Serious infections do not just trigger emergency granulopoiesis; they can fundamentally restructure the bone marrow’s progenitor landscape. In chronic tuberculosis models, mycobacterial infection expanded not only the earliest stem-cell-like population but also the granulocyte-monocyte progenitor compartment specifically. This expansion depended on inflammatory signaling molecules like TNF-α and IL-6 and on pattern-recognition pathways that detect bacterial components. When those signals were blocked, the progenitor expansion was markedly suppressed.
This remodeling of the progenitor pool means that a prolonged infection is not just drawing down existing supplies of neutrophils and monocytes; it is actively reprogramming the factory to increase myeloid output at the upstream level. That shift comes at a cost, since resources diverted to myeloid production may reduce other lineages, contributing to the anemia and immune dysfunction often seen in chronic infectious diseases.
Rethinking the Lineage Tree
The classic diagram of blood-cell development shows a neat tree: the stem cell at the top, a clean fork into myeloid and lymphoid branches, and further forks into specific cell types. Single-cell RNA sequencing is complicating that picture. When researchers analyzed individual blood cells as they committed to specific lineages, they found not discrete steps but a continuous spectrum of differentiation, with cells gradually shifting their gene expression profiles rather than flipping abruptly from one identity to another.21PubMed Central. Single-Cell RNA-Sequencing Reveals a Continuous Spectrum of Differentiation in Hematopoietic Cells
This matters practically because it means that the surface markers clinicians and researchers use to sort cells into categories are somewhat arbitrary boundaries drawn across what is really a smooth gradient. A “common myeloid progenitor” captured in one experiment might be at a slightly different point on the continuum than one captured in another. It also means the traditional branching tree, while still useful as a teaching tool, underestimates the flexibility of early progenitors. Some cells that look committed to one lineage retain the ability to shift course if the right signals arrive, a flexibility that likely underpins the body’s ability to rapidly redirect blood production during emergencies.
Mobilizing Myeloid Precursors for Transplant
When patients need a stem cell transplant, donors are often given a drug called G-CSF (granulocyte colony-stimulating factor) to push stem cells out of the bone marrow and into the bloodstream, where they can be collected. G-CSF does not just release generic stem cells; it preferentially expands and mobilizes myeloid-committed progenitors. Studies have shown that stem cells harvested from G-CSF-treated donors express significantly higher levels of myeloid surface markers compared to cells collected without the drug, and G-CSF increases the number of myeloid-committed colony-forming cells.22PubMed. Predominance of myeloid antigens in CD34-positive peripheral blood stem cells over those in bone marrow after administration of granulocyte colony-stimulating factor
This myeloid skew in the transplant product has clinical implications. It can speed up the recovery of neutrophils and platelets after transplant, which are the cell types patients most urgently need to avoid infections and bleeding in the early post-transplant period. At the same time, it means the transplanted cells are already biased toward myeloid output, a factor that may matter for long-term immune reconstitution. G-CSF is also used therapeutically outside of transplant settings, for instance to boost neutrophil counts in chemotherapy patients whose bone marrow has been temporarily suppressed.
Identifying Abnormal Myeloid Precursors in the Lab
When a hematologist suspects a myeloid malignancy, one of the key steps is identifying whether the precursor cells in the bone marrow are normal or abnormal. This is done through immunophenotyping, a technique that uses antibodies tagged with fluorescent markers to identify which proteins sit on the surface of each cell. Normal HSCs are defined by a specific combination of surface markers, while leukemia stem cells in conditions like AML are distinguished by the aberrant expression of markers that should not be present at that stage of development.23PubMed. Immunophenotypic features of early haematopoietic and leukaemia stem cells Detecting these abnormal precursors matters for diagnosis, for tracking how well treatment is working, and for catching early signs of relapse. The ability to spot a tiny population of aberrant myeloid precursors hiding among millions of normal cells has become one of the most powerful tools in blood cancer management.